Nabriva Therapeutics (NBRV) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Nabriva Therapeutics (NASDAQ: NBRV):

  • 12/3/2019 – Nabriva Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/25/2019 – Nabriva Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/25/2019 – Nabriva Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/19/2019 – Nabriva Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 11/15/2019 – Nabriva Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
  • 11/14/2019 – Nabriva Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/13/2019 – Nabriva Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC.
  • 11/5/2019 – Nabriva Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/30/2019 – Nabriva Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/16/2019 – Nabriva Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of NASDAQ:NBRV opened at $1.94 on Thursday. The company’s fifty day moving average is $1.95 and its 200-day moving average is $2.15. The company has a debt-to-equity ratio of 0.87, a quick ratio of 5.79 and a current ratio of 5.81. Nabriva Therapeutics PLC – has a 52 week low of $1.12 and a 52 week high of $3.27. The company has a market capitalization of $1.52 billion, a PE ratio of -1.19 and a beta of 2.43.

Nabriva Therapeutics (NASDAQ:NBRV) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. The firm had revenue of $6.92 million for the quarter, compared to analysts’ expectations of $1.23 million. Nabriva Therapeutics had a negative net margin of 910.45% and a negative return on equity of 171.36%. On average, analysts forecast that Nabriva Therapeutics PLC – will post -1.15 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. Sterling Investment Advisors Ltd. raised its stake in Nabriva Therapeutics by 100.0% in the 3rd quarter. Sterling Investment Advisors Ltd. now owns 20,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 10,000 shares during the last quarter. Woodard & Co. Asset Management Group Inc. ADV purchased a new stake in shares of Nabriva Therapeutics in the third quarter worth about $40,000. State Street Corp acquired a new stake in Nabriva Therapeutics during the third quarter worth about $65,000. Barclays PLC grew its holdings in Nabriva Therapeutics by 171,923.1% during the third quarter. Barclays PLC now owns 44,726 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 44,700 shares during the period. Finally, A.R.T. Advisors LLC purchased a new position in Nabriva Therapeutics during the second quarter valued at approximately $90,000. Institutional investors own 3.17% of the company’s stock.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

See Also: Blockchain

Receive News & Ratings for Nabriva Therapeutics PLC - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics PLC - and related companies with MarketBeat.com's FREE daily email newsletter.